Materias dentro de su búsqueda.
Mostrando 8,621 - 8,640 Resultados de 9,598 Para Buscar 'Zújar~', tiempo de consulta: 1.26s Limitar resultados
  1. 8621
    por Rosenberg, Philip, Hoskin, F. C. G.
    Publicado 1963
    “…D-Tubocurarine (curare) and acetylcholine (ACh) had been found to block electrical activity after treatment of squid giant axons with cottonmouth moccasin venom at a concentration which had no effect on conduction. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Demonstration of Increased Permeability as a Factor in the Effect of Acetylcholine on the Electrical Activity of Venom-Treated Axons
  2. 8622
    “…Adverse events (AEs) and European League Against Rheumatism (EULAR) responses were monitored every 4 weeks for 24 weeks. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
  3. 8623
    “…Patients who fulfilled both the 2010 ACR/EULAR criteria for RA classification and the 1997 ACR revised criteria for classification of SLE and received abatacept treatment for arthritis were retrospectively studied. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus
  4. 8624
    “…The statin-exposed status was negatively and very weakly correlated with EULAR response at 6 months (r = −0.073, P = 0.661) and 18 months (r = −0.197, P = 0.244). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Statins Do Not Influence Long-Term Rituximab Clinical Efficiency in Rheumatoid Arthritis Patients
  5. 8625
    por Felson, David T, LaValley, Michael P
    Publicado 2014
    “…The one element of this effort that has not optimized measurement of outcomes nor made it easier to detect the effect of treatments is the dichotomization of continuous measures of response, creating responders and non-responder definitions (for example, ACR20 responders; EULAR good responders). Dichotomizing response sacrifices statistical power and eliminates variability in response. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing
  6. 8626
    “…The 75 eligible patients were classified as EULAR good, moderate, and nonresponders with good agreement (61/75; 81%) between DAS28-CRP and DAS28-ESR (κ = 0.75 (95% CI: 0.63 to 0.88)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis
  7. 8627
    “…HCQ reduced ESR, IgG and IgM levels independently of the patients' IFN activation status. No differences in EULAR SS disease activity index or EULAR SS patient reported index scores were observed after HCQ treatment, even after IFN stratification. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial
  8. 8628
    “…The European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) and EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI) were calculated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren’s syndrome: An exploratory cross-sectional study
  9. 8629
    “…We compare the usefulness of the recently revised ACR/EULAR and Comprehensive criteria and discuss treatment options. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Supraglottic Localization of IgG4-Related Disease—Rare and Challenging Equity
  10. 8630
    “…In these cases, American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria may be insufficient to establish the diagnosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Eosinophilic Variant of Granulomatosis With Polyangiitis
  11. 8631
    “…Comparable findings applied to EULAR non-response criteria. CONCLUSIONS: This study demonstrates clinical utility for the use of baseline IRG expression levels as a predictive biomarker for non-response to RTX in RA.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
  12. 8632
    “…At T1, 47.3% of subjects failed to achieve LDA, and 29.3% did not have any EULAR-response. In multivariate analysis, significant associations were observed between no LDA and current smoking (adjusted odds ratio [adjOR] 1.79, P = .037), female gender (adjOR 1.68, P = .048), and higher DAS28 (adjOR 1.31, P = .013); and between no EULAR-response and current smoking (adjOR: 2.04, P = .019), age (adjOR: 0.72 per 10-years increases, P = .001), and higher erythrocyte sedimentation rate (adjOR: 0.49; P = .020). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs: Results from a retrospective cohort study
  13. 8633
    “…Here, we provide a comprehensive review of clinical trials that form the basis for the Kidney Disease: Improving Global Outcomes and EULAR/ERA-EDTA updated guidelines and present day trials that will change the landscape of lupus nephritis therapy in years to come. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Management of Lupus Nephritis: New Treatments and Updated Guidelines
  14. 8634
    “…RESULTS: In the 3C and 2C models, patients with RA were 1.92 (CI: 1.04 to 3.54) and 2.03 (CI: 1.09 to 3.78) times more likely to be classified as EULAR responders if they had high (75th quartile) pre-treatment levels of MRP8/14 compared with low (25th quartile). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
  15. 8635
    “…Major improvements in fatigue, pain and morning stiffness were observed in the first 4 weeks and further improved until week 24. DAS28, EULAR and ACR responses at week 24 did not differ between RF-positive and RF-negative patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
  16. 8636
    “…CONCLUSIONS: In a population of Danish RA patients, we confirm the NLRP3 gene as associated with EULAR anti-TNF response as previously reported. The NLRP3 variant (T) allele is associated with lower treatment response, in particular among current smokers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anti-TNF Treatment Response in Rheumatoid Arthritis Patients Is Associated with Genetic Variation in the NLRP3-Inflammasome
  17. 8637
    por Jani, Meghna, Chinoy, Hector, Warren, Richard B., Griffiths, Christopher E. M., Plant, Darren, Fu, Bo, Morgan, Ann W., Wilson, Anthony G., Isaacs, John D., Hyrich, KimmeL., Barton, Anne, Prouse, P. J., Moitra, R. K., Shawe, D. J., Nisar, M., Fairburn, K., Nixon, J., Barnes, T., Hui, M., Coady, D., Wright, D., Morley, C., Raftery, G., Bracewell, C., Bridges, M., Armstrong, D., Chuck, A. J., Hailwood, S., Kumar, N., Ashok, D., Reece, R., O'Reilly, S. C., Ding, T., Badcock, L. J., Deighton, C. M., Raj, N., Regan, M. R., Summers, G. D., Williams, R. A., Lambert, J. R., Stevens, R., Wilkinson, C., Kelly, C. A., Hamilton, J., Heycock, C. R., Saravanan, V., Cope, A., Garrood, T., Ng, N., Kirkham, B., Green, M., Gough, A., Lawson, C., Das, D., Borbas, E., Wazir, T., Emery, P., Bingham, S., Bird, H. A., Conaghan, P.G., Pease, C. T., Wakefield, R. J., Buch, M., Bruce, I., Gorodkin, R., Ho, P., Parker, B., Smith, W., Jenkins, E., Mukhtyar, C., Gaffney, K., Macgregor, A. J., Marshall, T., Merry, P., DeSilva, C., Birrell, F. N., Crook, P. R., Szebenyi, B., Bates, D., James, D., Gillott, T., Alvi, A., Grey, C., Browning, J., McHale, J. F., Gaywood, I.C., Jones, A. C., Lanyon, P., Pande, I., Doherty, M., Gupta, A., Courtney, P. A., Srikanth, A., Abhishek, A., Das, L., Pattrick, M., Snowden, H. N., Bowden, A. P., Smith, E. E., Klimiuk, P., Speden, D. J., Naz, S., Ledingham, J. M., Hull, R. G., McCrae, F., Cooper, A., Young‐Min, S. A., Wong, E., Shaban, R., Woolf, A. D., Davis, M., Hutchinson, D., Endean, A., Mewar, D., Tunn, E. J., Nelson, K., Kennedy, T. D., Dubois, C., Pauling, J., Korendowych, E., Jenkinson, T., Sengupta, R., Bhalla, A., McHugh, N., O'Neil, T., Herrick, A. L., Jones, A. K., Cooper, R. G., Dixon, W. G., Harrison, B., Buckley, C. D., Carruthers, D. C., Elamanchi, R., Gordon, P. C., Grindulis, K. A., Khattak, F., Raza, K., Situnayake, K., Akil, M., Till, S., Dunkley, L., Tattersall, R., Kilding, R., Tait, T., Maxwell, J., Till, S., Kuet, K.-P., Plant, M. J., Clarke, F., Fordham, J. N., Tuck, S., Pathare, S. K., Paul, A., Marguerie, C. P., Rigby, S. P., Dunn, N., Abbas, I., Filer, C., Abernethy, V. E., Clewes, A. R., Dawson, J. K., Kitas, G., Erb, N., Klocke, R., Whallett, A. J., Douglas, K., Pace, A., Sandhu, R., John, H., Shand, L., Lane, S., Foster, H., Griffiths, B., Griffiths, I., Kay, L., Ng, W.-F., Platt, P. N., Walker, D. J., Peterson, P., Lorenzi, A., Friswell, M., Thompson, B., Lee, M., Pratt, A., Hopkinson, N. D., Dunne, C. A., Quilty, B., Marks, J., Mukherjee, S., Mulherin, D., Chalam, S. V., Price, T., Sheeran, T., Venkatachalam, S., Baskar, S., Al- Allaf, W., McKenna, F., Shah, P., Filer, A., Bowman, S. J., Jobanputra, P., Rankin, E. C., Allen, M., Chaudhuri, K., Dubey, S., Price‐Forbes, A., Ravindran, J., Samanta, A., Sheldon, P., Hassan, W., Francis, J., Kinder, A., Neame, R., Moorthy, A., Bukhari, M., Ottewell, L., Palkonyai, E., Hider, S., Hassell, A., Menon, A., Dowson, C., Kamath, S., Packham, J., Dutta, S., Price, S., Roddy, E., Paskins, Z., O'Reilly, D. T., Rajagopal, V., Bhagat, S., Chattopadhyay, C. B., Green, M., Quinn, D., Isdale, A., Brown, A., Saleem, B., Foo, B., Al Saffar, Z., Koduri, G.
    Publicado 2015
    “…At 3 months, antidrug antibodies and low adalimumab levels are significant predictors of no response according to the EULAR criteria at 12 months.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis
  18. 8638
    “…The primary endpoint was a good or moderate EULAR response assessed after 1 year of follow-up, given at least 3 months of treatment with a csDMARD. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
  19. 8639
    “…Results: This cohort included 38 ADM patients and 26 HDM patients. 2017 EULAR/ACR criteria classified 67.2% of patients with CADM into probable or definite DM. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department
  20. 8640
    “…The formal SLE diagnosis was established according to the EULAR/ACR 2019 criteria; with a score of 12 (AIHA: 4; positive antiphospholipid antibodies: 2; positive anti-Sm antibodies: 6). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    49 Autoimmune hemolytic anemia revealing a familial systemic lupus erythematosus
Herramientas de búsqueda: RSS